Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hairy cell leukemia that is resistant to treatment.
10 clinical trials registered, 4 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE2, 3 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT00412594](https://clinicaltrials.gov/study/NCT00412594) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia |
PHASE2 |
M.D. Anderson Cancer Center |
RECRUITING |
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825) | Registry of Older Patients With Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT01137643](https://clinicaltrials.gov/study/NCT01137643) | Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT06965114](https://clinicaltrials.gov/study/NCT06965114) | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
5 publications have been identified in PubMed for refractory hairy cell leukemia. Research spans Other (40%), Clinical Trial Publication (40%), and Case Report / Case Series (20%).
Schroeder B (2026). [PMID: 41060318](https://pubmed.ncbi.nlm.nih.gov/41060318/). *Blood*. [Clinical Trial Publication]
De Carolis L (2025). [PMID: 41246450](https://pubmed.ncbi.nlm.nih.gov/41246450/). *Hemasphere*. [Other]
Unknown (2024). [PMID: 39509119](https://pubmed.ncbi.nlm.nih.gov/39509119/). *Blood*. [Other]
Tadmor T (2024). [PMID: 38247446](https://pubmed.ncbi.nlm.nih.gov/38247446/). *Leuk Lymphoma*. [Case Report / Case Series]
Yiğit Kaya S (2024). [PMID: 38599153](https://pubmed.ncbi.nlm.nih.gov/38599153/). *Leuk Res*. [Clinical Trial Publication]
AI-curated news mentioning refractory hairy cell leukemia
Updated Sep 15, 2026
A recent publication provides an update on the diagnosis, risk-stratification, and treatment of hairy cell leukemia, highlighting advancements in understanding the disease. This comprehensive review outlines current best practices and emerging therapies for managing this rare hematological condition.
Recent research indicates that BRAF V600E-mutated marginal zone lymphoma may share characteristics with hairy cell leukemia. This discovery could impact diagnostic approaches and treatment strategies for these overlapping conditions.
A multicenter retrospective cohort study examines real-world treatment outcomes in hairy cell leukemia, highlighting the role of BRAF inhibitor therapy. This research provides valuable insights into treatment efficacy and patient management strategies.